Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. AstraZeneca

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

AstraZeneca

15 Jul 2021 17:30

RNS Number : 4287F
FTSE Russell
15 July 2021
Ā 

OĀ 

Ā 

Ā 

Ā 

AstraZeneca (UK): Acquisition of Alexion Pharmaceuticals (USA)Changes in FTSE UK Index Series

15 July 2021

Subject to the completion of the cash and stock acquistion of Alexion Pharmaceuticals (USA, non-constituent) by AstraZeneca (UK, constituent), please see details of affected indexes and effective dates below:

Ā 

Ā 

Index

Effective FromStart of Trading

FTSE 100 Index

21 July 2021

FTSE 350 Index

21 July 2021

FTSE All-Share Index

21 July 2021

FTSE 350 Higher Yield Index

21 July 2021

Techmark All Share Index

21 July 2021

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

Ā 

Alternatively please visit our website at www.ftserussell.com

Ā 

Terms of Use | Copyright Ā© 2021 FTSE Russell

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
FTSSFFFMIEFSEFW
111213141516171819
Date   Source Headline
20th Jan 20207:00 amRNSImfinzi, tremelimumab granted ODD in liver cancer
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
111213141516171819

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
LWI
Lowland Inv.
LSE
-0.58%
HLMA
Halma
LSE
-4.39%
BPM
B.p Marsh
LSE
1.59%
MTO
Mitie
LSE
-3.06%
CTY
City Of London Investment
LSE
0.18%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
EZJ
easyJet
LSE
0.34%